Pfizer inc(PFE.US AI Earnings Summary)
PFE AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Management Expectations: Both revenue and earnings for this quarter exceeded management's internal expectations. Highlights included $16.6B in revenue and adjusted EPS of $0.87, primarily driven by 32% operational growth from new launches and acquired products.
- Vs. Previous Guidance: Last quarter's guidance was on a full-year basis (full-year revenue of $60.5B–$62.5B, full-year adjusted EPS of $2.80–$3.00). This quarter's actual figures ($16.6B revenue, $0.87 adjusted EPS) are not directly comparable to full-year guidance. CFO Cécile Guegan explicitly stated that performance this quarter was better than management's expectations.
- In One Sentence: PFIZER INC (PFE) raised its full-year guidance driven by strong momentum in non-COVID products and acquired assets, highlighting commercial execution and cost control effectiveness.
Quarterly Highlights
Driven by the dual engines of non-COVID products and the launch/acquisition portfolio, management reported that both revenue and adjusted EPS for the quarter exceeded their expectations.
Steady Growth in Non-COVID Products, Quarterly Revenue Exceeds Management Expectations: 2026 Q3 total revenue was $16.6B, with non-COVID products growing 7% at constant exchange rates (CER), contributed by ELIQUIS, the VYNDAQEL family, NURTEC, and LORBRENA. CFO Cécile Guegan stated that quarterly revenue was "better than management's expectations," leading to a $1.5B increase in the full-year revenue guidance midpoint to $62B–$64B.
Accelerated Growth in Launch and Acquisition Portfolio, Seagen Assets Shine: Launched and acquired products contributed $3.8B this quarter, growing 32% CER. The Seagen legacy portfolio grew 39% YoY in the U.S., with PADCEV up $255M, NURTEC up $135M (33% CER growth), and LORBRENA up $114M. CEO Albert Bourla noted that oncology commercial coverage depth has significantly improved since the Seagen integration.
Adjusted EPS Exceeds Management Expectations, Gross Margin Remains High: 2026 Q3 adjusted diluted EPS was $0.87, which management stated was above their expectations even after absorbing a $0.10 per share charge from the Innovent transaction. Adjusted gross margin reached 77%, and adjusted cost of goods sold as a percentage of revenue fell from 23.9% to 23.2% (down 0.7 percentage points), reflecting product mix improvement and continuous cost control.
Full-Year Adjusted EPS Guidance Raised and Narrowed: Full-year adjusted diluted EPS guidance was raised and narrowed from $2.80–$3.00 to $2.95–$3.05, representing a $0.10 increase at the midpoint while absorbing the $0.10 per share impact from the Innovent deal. Management reaffirmed the full-year adjusted gross margin expectation of approximately 73%–77%.
Cost Alignment Program Ahead of Schedule, Phase 2 Savings Target Launched: The first phase of the cost improvement program (targeting $7.2B in net savings) is expected to complete nearly all goals by the end of 2026. Phase 2 has been launched, aiming for an additional $2.5B in net savings from 2027 to 2029, covering SI&A and manufacturing costs to buffer margin pressure during the Loss of Exclusivity (LOE) transition period.
ELREXFIO Phase 3 Trial Double Positive Readout, Increased Confidence in Multiple Myeloma Pipeline: The MagnetisMM-32 trial showed that ELREXFIO monotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to three standard-of-care treatments. At the interim analysis, over 75% of patients had not progressed or died, with an 18-month PFS rate of approximately 68%. Chief Scientific Officer Chris Boshoff noted that two positive Phase 3 results strengthen confidence in moving ELREXFIO into earlier lines of treatment.
Obesity Pipeline Progresses, Berobenatide Phase 3 Program Fully Underway: In 2026, the company plans to advance 10 active or planned Phase 3 trials for berobenatide, including a study evaluating a switch from weekly therapy to a monthly GLP-1 peptide. The Phase 2b trial for the amylin combination program (SOLIS-1) has completed enrollment, with efficacy data expected in H2 2027. Management reaffirmed the first berobenatide approval goal for 2028.
Robust Cash Flow, Disciplined Capital Allocation: Cumulative operating cash flow for the first three quarters of 2026 was approximately $8.8B. During this period, $9.2B was invested in internal and external R&D, and $7.3B was returned to shareholders via quarterly dividends. Leverage stood at 2.6x at quarter-end, slightly below the 2026 target of 2.7x. After the Innovent transaction, remaining business development (BD) capacity is approximately $6B.